Zymeworks (ZYME) Liabilities and Shareholders Equity (2021 - 2026)

Zymeworks (ZYME) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $478.2 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 12.38% year-over-year to $478.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.6 billion (down 13.8% YoY), and the FY2025 full-year result was $346.5 million, down 25.17% from the prior year.
• Liabilities and Shareholders Equity improved to $478.2 million in Q1 2026, from $346.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $648.7 million in Q4 2022 to a low of $300.3 million in Q3 2022.
• A 5-year average of $491.0 million and a median of $487.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 85.29% in 2023 and decreased 25.17% in 2025, its largest moves.
• Tracing ZYME's Liabilities and Shareholders Equity over 5 years: stood at $648.7 million in 2022, then dropped by 10.46% to $580.9 million in 2023, then dropped by 20.28% to $463.1 million in 2024, then declined by 25.17% to $346.5 million in 2025, then jumped by 38.0% to $478.2 million in 2026.
• Business Quant data shows ZYME's Liabilities and Shareholders Equity at $478.2 million in Q1 2026, $346.5 million in Q4 2025, and $397.3 million in Q3 2025.